This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PF-4136309, INCB8761
Description: PF-4136309 is an orally active antagonist of the chemokine receptor CCR2.
Deal Structure: Incyte and Pfizer announced in November 2005 that the two companies have entered into a global collaborative research and license agreement for the development, manufacture and marketing of Incyte's oral CCR2 antagonists, the most advanced of which is INCB3284.
Pfizer gains exclusive worldwide development and commercialization rights to Incyte's portfolio of CCR2 antagonist compounds. Pfizer's rights extend to the full scope of potential indications, with the exception of multiple sclerosis and one other undisclosed indication, where Incyte retains exclusive worldwide rights, along with certain compounds. Incyte will not have obligations to Pfizer on pre-clinical development candidates it selects for pursuit in these indications. Pfizer will also provide research funding to Incyte to support the continued expansion of the CCR2 compound portfolio.
Incyte will receive an upfront payment of $40 million and will be eligible to receive additional milestone payments of up to $743...See full deal structure in Biomedtracker
Partners: Incyte Corporation
Additional information available to subscribers only: